Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. The company specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other significant diseases. Its flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor and is approved in the U.S. for multiple oncology indications. These include combination therapies with Velcade® (bortezomib) and dexamethasone for multiple myeloma, as well as treatments for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Recent achievements highlight the company's commitment to advancing its late-stage clinical pipeline. Notably, Karyopharm has been at the forefront in evaluating selinexor's efficacy in combination therapies for multiple myeloma, endometrial cancer, and myelofibrosis. The company recently reported long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib in myelofibrosis patients, showing promising results in spleen volume and symptom reduction.
Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the company managed to maintain steady growth and focused resources on its high-potential pipeline. With a cash position of $192.4 million as of December 31, 2023, Karyopharm is well-positioned to continue its innovative research and development efforts.
Karyopharm's collaborations with global partners, including Antengene, Menarini, Neopharm, and FORUS, have extended the reach of XPOVIO to various international markets such as Europe, China, South Korea, and Israel. This international expansion underscores the global demand for innovative cancer therapies.
For more information, please visit www.karyopharm.com.
Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. Strong joins from Argot Partners, where he served as Managing Director advising biopharmaceutical companies. His previous experience includes roles as investor relations lead at Tenet Healthcare, CFO of Tenet's Massachusetts Market, and equity research positions at Lehman Brothers and Barclays.
The company emphasizes Strong's experience will be valuable as they approach important milestones in 2025, particularly in advancing their late-stage pipeline and building on their multiple myeloma foundation. Strong holds an MBA from Harvard Business School and a B.S. in Finance from Rutgers University.
Karyopharm Therapeutics (Nasdaq: KPTI) announced it is in discussions with the FDA regarding the evolving treatment landscape in endometrial cancer and potential implications for their Phase 3 XPORT-EC-042 trial. Due to these ongoing discussions, the company will not address its endometrial cancer program at the Piper Sandler Healthcare Conference. An update will be provided after the FDA discussion concludes.
Karyopharm Therapeutics has announced the granting of 4,800 restricted stock units (RSUs) to two newly-hired employees as of November 30, 2024. The RSUs were granted under the company's 2022 Inducement Stock Incentive Plan, following Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, with 33 1/3% vesting annually. Full vesting is subject to continued employment, with immediate vesting possible in case of qualifying termination following a change in control event.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior management team will engage in a fireside chat on Tuesday, December 3 at 11:30 a.m. ET in New York.
The event will be accessible via live webcast in the Investor section of Karyopharm's website under 'Events & Presentations,' with replay availability after the event.
Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Kristin Abate as Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Abate, who has been serving as interim principal financial officer and interim principal accounting officer since November 6, 2024, will continue as interim principal financial officer. With over 15 years of finance experience, she joined Karyopharm in July 2019 and previously worked at PricewaterhouseCoopers LLP from 2007 to 2019. She holds a B.S. in Business Administration from Bryant University and a Masters of Science in Accountancy from Boston College.
Karyopharm Therapeutics (Nasdaq: KPTI) announced its upcoming presentations at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, December 7-10, 2024. The presentations will showcase data on selinexor across multiple studies.
The presentations include two posters: one examining the efficacy and safety of selinexor, pomalidomide, and dexamethasone (SPd) for relapsed/refractory multiple myeloma, and another studying selinexor's effect on ruxolitinib refractory myelofibrosis. Additionally, their partner Antengene will present data comparing weekly selinexor, bortezomib, and dexamethasone versus twice-weekly bortezomib and dexamethasone in Chinese patients with relapsed/refractory multiple myeloma.
Karyopharm Therapeutics reported Q3 2024 financial results with total revenue of $38.8 million, including U.S. XPOVIO net product revenue of $29.5 million. The company narrowed its full-year 2024 guidance, projecting total revenue of $145.0-155.0 million and U.S. XPOVIO net product revenue of $110.0-115.0 million. Following FDA alignment, the Phase 3 SENTRY trial in myelofibrosis will use Absolute Change in Total Symptom Score as a co-primary endpoint, with top-line data expected in 2H 2025. The company reported a net loss of $32.1 million for Q3 2024 and had cash reserves of $133.9 million as of September 30, 2024.
Karyopharm Therapeutics (Nasdaq: KPTI) has granted 10,500 restricted stock units (RSUs) to three newly-hired employees as of October 31, 2024. The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan and will vest over three years, with 33 1/3% vesting annually. The grants serve as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs include accelerated vesting provisions in case of employment termination following a change in control event.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its third quarter 2024 financial results announcement for Tuesday, November 5, 2024. The management team will host a conference call and audio webcast at 8:00 a.m. ET on the same day. The presentation will include financial results and company updates, with dial-in numbers provided for both local and international participants. A live webcast with slides will be available on the company's investor website, with an archived version accessible approximately two hours after the event.
Karyopharm Therapeutics (Nasdaq: KPTI) announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed promising results with 79% of patients achieving SVR35 and an average Abs-TSS improvement of 18.5 points at week 24 when combining selinexor with ruxolitinib, compared to historical data showing less than 50% SVR35 achievement with JAK inhibitor monotherapy.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
What is Karyopharm Therapeutics' main focus?
What is XPOVIO® (selinexor)?
What recent achievements has Karyopharm reported?
Who are Karyopharm's global partners?
What are Karyopharm's financial highlights?
What are the key indications for XPOVIO?
What is the significance of Karyopharm's research on nuclear export proteins?
How does Karyopharm support clinical trials and research?
What are the safety considerations for XPOVIO?
How can I get more information about Karyopharm's products or clinical trials?
